Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
24 October 2024 | Story Anthony Mthembu | Photo Stephen Collett
Sanlam and Santam Economist of the Year’ competition
From left to right: Jaco Geldenhuys, Senior Business Manager at Sanlam; Mokai Malope, secured second place; Reatile Seekoei, winner of the 2024 Sanlam and Santam Economist of the Year competition; Tricia Khoza, secured third place; and LC Olivier, Senior Business Manager at Santam.

The inaugural ‘Sanlam and Santam Economist of the Year’ competition gala, held on 18 October 2024 at the University of the Free State (UFS) Bloemfontein Campus, has been hailed as a significant opportunity for growth. Hosted by the Department of Economics and Finance in the Faculty of Economic and Management Sciences (EMS), in collaboration with Sanlam and Santam, the event celebrated the exceptional talents of young economists.

The gala brought together representatives from Sanlam and Santam, faculty members, the top 10 competition finalists, and the department’s leading academic performers from each year group. Jaco Geldenhuys, Senior Business Manager at Sanlam, commended the participants for their dedication, noting: ’Today, we not only recognise your academic excellence but also the potential, positive impact you will have in the world.’’

Prof Johan Coetzee, Chairperson of the Department of Economics and Finance, echoed this sentiment, emphasising that the competition aims to equip graduates to become global citizens who can solve problems, think critically, and communicate effectively in a constantly changing world.

What transpired during the event

The top 10 finalists presented their analysis in a 6-minute presentation before a panel of economists from the department, demonstrating their understanding of the macroeconomic environment, the methods they used to predict key macroeconomic indicators, and the lessons they gained from the process. After these presentations, the top three finalists were chosen and were required to respond to questions from the panel, determining the overall winner.

The top three included Tricia Khoza, who secured third place, Mokai Malope, who earned second place; and Reatile Seekoei, who was named the 2024 ‘Sanlam and Santam Economist of the Year.

All three finalists expressed their gratitude for the opportunity. Seekoei shared: “Competitions like this are invaluable because they prepare us for the working world. We have gained several graduate attributes we were introduced to at the start of our academic journey.’’

In addition to recognising the top three finalists, the department also awarded certificates to its top academic achievers, ranging from first-year undergraduate students to master's candidates.

Paving the way for the future

For many of the participants, the competition provided an invaluable glimpse into the professional world, offering them a chance to apply their classroom learning to real-world economic challenges. Geldenhuys encouraged the young economists to use their knowledge to challenge inequality, promote fairness, and drive innovation and sustainable growth.

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept